The case is reported of a 30-year-old multigravida, with insignificant history and stable vital signs, admitted to the labour room for normal vaginal delivery of twins. She received combined spinal epidural analgesia (bupivacaine plus fentanyl) for 3 h. Following uneventful delivery she received 0.2 mg methylergonovine maleate, intramuscularly. Nausea and vomiting occurred 70 min after placenta delivery, heart rate decreased, arterial blood pressure increased and there was chest pain. After excluding cardiac ischaemia, 0.5 mg atropine sulphate was administered intravenously. Chest pain improved but heart rate and blood pressure increased more than expected. The patient had mild headache and nausea, and antiemetic 4 mg ondansetron was given intravenously. Continuous monitoring for 4 h showed spontaneous chest pain relief and blood pressure improvement. In conclusion, serious delayed side-effects arising from methylergonovine maleate can occur in young, normal patients and close monitoring is required. Intravenous atropine sulphate following methylergonovine maleate administration may lead to severe hypertension and tachycardia.
Introduction
Atropine is a parasympatholytic drug frequently used in anaesthesia for many indications and it is the drug of choice for severe and symptomatic sinus bradycardia. 1 The side-effects of atropine include mild-tomoderate tachycardia, dry mouth, blurred vision, flushing and sometimes headache.
Methylergonovine maleate is a drug commonly used to control postpartum haemorrhage and it has many side-effects, including tachycardia, hypertension, nausea, vomiting and even bradycardia and hypotension. Diffuse coronary spasm can also occur, leading to a decrease in the coronary diameter of 15 -20% in normal patients. 2 Myocardial infarction and even cardiac arrest following intravenous, intramyometrial and intramuscular injection have also been reported. 2, 3 In the present case study, delayed but serious sinus bradycardia occurred after SM Ibrahim, E Mustafa, A Louon Postpartum severe bradycardia intramuscular methylergonovine maleate administration. Treatment of severe bradycardia with a small dose of atropine led to persistent and severe tachycardia and hypertension. To the best of our knowledge, no previous case report has reported an association between methylergonovine maleate and the side-effects of atropine.
Case report
A 30-year-old multigravida (gravida 6, para 5) with a gestational age of 37 weeks plus 2 days had a twin pregnancy. She was admitted to the labour room for attempted normal vaginal delivery.
The patient had an insignificant history apart from asymptomatic superficial bilateral varicose veins in both lower limbs. Previous obstetric history showed no complications during or after previous deliveries. The patient's vital signs were stable: systolic/diastolic blood pressure, 110/72 mmHg; heart rate, 73 beats/min; respiratory rate, 20 breaths/min; and temperature, 36.5°C. Obstetric examination indicated the cervix was 5 cm dilated and 80% effaced, membranes were intact and both babies had a cephalic presentation. The patient had an irrelevant history, with chest, heart and spine being clinically free of disorders; examination of the patient's back and spine showed no apparent abnormalities. Coagulation profile and blood investigations were all within normal limits.
The patient received epidural analgesia on her request and the procedure was uneventful. Combined spinal epidural analgesia using a loss of resistance to fluid, needle-through-needle technique was performed. This was uneventful and 0.5 ml heavy bupivacaine along with 25 µg fentanyl was injected into the subarachnoid space. Epidural infusion mixture containing 10 ml bupivacaine 0.5%, 100 µg fentanyl and 38 ml normal saline was prepared and started at a rate of 6 ml/h. The total dosages administered were 48 mg of bupivacaine and 95 µg of fentanyl. Pain relief was excellent and sensory block reached T 10 level. No motor block was noticed and no top-up dose was required. The total time of epidural analgesia was 3 h. Normal vaginal delivery was uneventful, without instrumental assistance resulting in two babies with Apgar scores of (9/10). The patient was haemodynamically stable during the whole course of epidural analgesia and also during labour.
The patient received 0.2 mg methylergonovine maleate intramuscularly in a single dose, as per routine protocol following normal vaginal delivery of twins. At 70 min after delivery of the placenta she felt nauseous and vomited once. A 12-lead electrocardiogram (ECG) showed that her heart rate had decreased to 36 beats/min, without obvious cause, with sinus bradycardia but no ischaemic changes ( Fig.  1A) : PR interval 116 ms and QRS duration 81 ms. Arterial blood pressure was also increased (before delivery, 142/84 mmHg; after delivery, 187/119 mmHg). The patient felt faint and had non-specific mild-to-moderate chest pain, which was vague but generally located above the lower sternum; she denied any history of similar pain. Chest pain, bradycardia and fainting lasted for 90 min. Arterial blood gases showed no hypoxaemia or hypercapnia and her chest X-ray was normal. There was no sign of local anaesthetic toxicity and no lower limb motor block.
Evaluation by a cardiologist and physician excluded any ischaemic cardiac aetiology in the patient. With the persistence of absolute bradycardia, chest pain and fainting, and after exclusion of any symptoms and signs of cardiac ischaemia, 0.5 mg atropine sulphate was given slowly SM Ibrahim, E Mustafa, A Louon Postpartum severe bradycardia via intravenous infusion. Chest pain improved 2 min after atropine administration, but heart rate increased much more than was expected, reaching 119 beats/min ( Figs 1B and 2 ). Blood pressure also increased (up to 187/119 mmHg). The previous symptoms of chest pain were relieved, but the patient started to complain of mild headache and nausea once again; antiemetic therapy (4 mg ondansetron) was given intravenously. The 12-lead ECG was repeated many times and showed a PR interval of 124 ms and QRS duration of 85 ms. The patient was again assessed by the cardiologist and signs or symptoms of cardiac pathology were excluded. Continuous close monitoring of blood pressure and continuous heart tracing for 4 h A B
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showed relief of chest pain and spontaneous alleviation of high blood pressure without any further medication. The patient was transferred to the post-natal ward and observed for 48 h during which she showed no further symptoms or ECG changes. She was then discharged home.
Discussion
Methylergonovine is an ergot alkaloid that is commonly used to control postpartum haemorrhage and to help uterine contraction. It has many side-effects, with headache, nausea and vomiting occurring occasionally. Rarely observed reactions include acute myocardial infarction, transient chest pain, arterial spasm (coronary and peripheral), bradycardia, tachycardia, dyspnoea, haematuria, thrombophlebitis and water intoxication. 3 Although myocardial infarction and cardiac arrest are very rare, in seven previous cases that recorded serious cardiac events after methylergonovine injection, patients had at least one or more predisposing factors for ischaemic heart disease. 2 This was not the case with our patient, who had no predisposing factors. In addition, she had the advantage of having received epidural analgesia, which may cause hypotension and help with blood pressure control in hypertensive patients. 4 The onset of action of methylergonovine occurs 2 -5 min after administration and lasts for about 3 h, peaking at 12 -36 min. 5 In our patient, nausea and vomiting started > 1 h after methylergonovine intramuscular injection, followed by absolute bradycardia. A new guideline of the European Resuscitation Council (ERC) 1 recommends giving 0.5 mg atropine intravenously in cases of symptomatic bradycardia, with repeat doses up to 3 mg to ensure complete block of vagal stimulation and vagal reflex.
Although our patient received only 0.5 mg atropine, she suddenly developed severe tachycardia and her arterial blood pressure increased to a serious level, reaching 187/119 mmHg. Smaller doses of atropine (< 0.5 mg in adults) are not recommended as they may increase the risk of bradycardia. 6 Serious side-effects due to methylergonovine have been reported previously, occurring a few minutes after intravenous injection 5 and a maximum of 20 min after intramuscular injection. 7 In one case report after regular multiple intramuscular injections of 0.4 mg methylergonovine maleate every 8 h for 48 h, the patient developed acute chest pain and pulmonary oedema accompanied by ECG, chest X-ray and angiography findings of acute coronary occlusion. 8 To the best of our knowledge, our case study is the first to report major side-effects (absolute sinus bradycardia, 36 beats/min) after a single dose of 0.2 mg methylergonovine via intramuscular injection, followed by severe tachycardia and severe hypertension when the patient was treated with a small dose of atropine. Since the patient had no previous history of gastric disorder, the epigastric pain, nausea and vomiting were most probably due to delayed complications of intramuscular methylergonovine injection rather than due to a local lesion in the stomach. Cardiac origin of the chest pain was also excluded by clinical signs and symptoms, serial 12-lead ECG recordings and by continually monitoring the patient for > 4 h. From this we can conclude that delayed serious side-effects of methylergonovine, even at a low dose (0.2 mg intramuscularly), can occur in normal patients who are young and patients require close monitoring for a sufficient period of time, irrespective of the administration route. Furthermore, intravenous atropine
